Category: Parkinsonism, Atypical: PSP, CBD
Objective: Objective: PSP patients typically show reduced amplitude and velocity of vertical saccades, but saccadic abnormalities have also been reported in PD. We investigated the amplitude and peak velocity of of upward, downward and vertical saccades (up and downward saccades averaged) in progressive supranuclear palsy (PSP) and Parkinson’s disease (PD) patients, to assess the sensitivity and specificity of each quantitative parameter in distinguishing between these two diseases
Background: Background: The video-oculography (VOG) is a well-recognized and recommended technique to evaluate ocular dysfunction in PSP; however, it is still unknown which quantitative VOG parameter is the most suitable for PSP diagnosis.
Method: Methods: Fifty-one PSP patients, 113 PD patients, and 40 controls were enrolled. The diagnosis was performed on a clinico-radiological (Magnetic Resonance Parkinsonism index, MRPI and MRPI 2.0) basis to maximize the diagnostic certainty. We used VOG to assess the diagnostic performances of saccadic amplitude, peak velocity, and their product (AxV) in upward or downward direction and in vertical gaze (upward and downward averaged) in distinguishing PSP from PD patients.
Results: Results: PSP patients showed significantly reduced amplitude and peak velocity of ocular saccades both in upward and downward directions compared to PD and healthy subjects. In PD patients, amplitude in upward gaze was significantly lower than in controls. In vertical gaze, the peak velocity showed 99.1% specificity and 54.7% sensitivity for PSP classification. The AxV product showed high specificity (94.7%) and sensitivity (84.3%) and yielded higher accuracy (91.5%) than velocity and amplitude used alone in distinguishing PSP from PD.
Conclusion: Conclusions: Our study demonstrates that the peak velocity of vertical saccades was a very low sensitive parameter and cannot be used alone for PSP diagnosis. A new index combining amplitude and peak velocity in vertical gaze seems the most suitable video-oculographic biomarker for differentiating PSP from PD and controls.
To cite this abstract in AMA style:
A. Quattrone, M. Crasà, M. Morelli, B. Vescio, A. Augimeri, V. Gramigna, A. Quattrone. Video-oculographic biomarkers for evaluating vertical ocular dysfunction in progressive supranuclear palsy [abstract]. Mov Disord. 2022; 37 (suppl 2). https://www.mdsabstracts.org/abstract/video-oculographic-biomarkers-for-evaluating-vertical-ocular-dysfunction-in-progressive-supranuclear-palsy/. Accessed June 14, 2025.« Back to 2022 International Congress
MDS Abstracts - https://www.mdsabstracts.org/abstract/video-oculographic-biomarkers-for-evaluating-vertical-ocular-dysfunction-in-progressive-supranuclear-palsy/